Cardiovascular Diseases (CVD)CKM-LCBPNCT07547098

Study on Construction of Whole Lifecycle Cohort, Big Data Management and Clinical Prognosis of Cardio-Renal-Metabolic (CKM) Syndrome

An observational study of Cardiovascular Diseases (CVD) and Chronic Kidney Disease, run by First Affiliated Hospital of Fujian Medical University at 1 site in China.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts

Official record

Search all trials

Trial summary

Who is it for?: Ages 18 to 80 years
Conditions the study is for: Cardiovascular Diseases (CVD), Chronic Kidney Disease, Metabolic Diseases
How many people: 8,000 participants
Where: 1 siteChina
Study dates: 1 Mar 2026to 28 Feb 2031
How long will I take part?: 5 Years
Phase: Observational
Are there results?: Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

Ages 18 to 80 years
All sexes
No healthy volunteers
Adult, Older adult

Study population: Hospital-based adult CKM-related inpatients at the First Affiliated Hospital of Fujian Medical University with available clinical and multimodal examination data for longitudinal registry follow-up.

Who may be able to join

Age 18 years or older.
Inpatient record available at the First Affiliated Hospital of Fujian Medical University with retrievable identifiers for data linkage.
Cardiovascular disease, kidney disease, metabolic disease, or key examination/laboratory information supporting CKM phenotyping.
Willingness to participate and provision of written informed consent.
Ability to complete baseline assessment and follow-up.
Full civil capacity and ability to understand study information.

Who cannot join

Refusal to provide written informed consent.
Severe psychiatric disease or cognitive impairment precluding participation.
End-stage disease with expected survival less than 1 year.
Long-term absence more than 6 months preventing reliable follow-up.
Participation in another clinical study that may interfere with endpoint adjudication.
Missing key fields preventing linkage of examinations, imaging, and outcomes.

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Dajun Chai contact

008659187981637

dajunchai-fy@fjmu.edu.cn

Hailin Zhang contact

824224843@qq.com

China1 site, 1 recruiting

The First Affiliated Hospital of Fujian Medical University
Fuzhou, Fujian, 350011
Hailin Zhang, 008659187981637, 824224843@qq.com
Recruiting

Other trials in China

About this study

This is a single-center observational registry study aiming to establish a structured clinical and multimodal imaging database for cardiovascular-kidney-metabolic (CKM) populations and to support lifecycle follow-up and outcome management. Adult patients aged 18-80 years with cardiovascular, kidney, and/or metabolic diseases or key data for CKM phenotyping will be enrolled at the First Affiliated Hospital of Fujian Medical University. The study integrates retrospective data entry and prospective follow-up, including clinical records, laboratory tests, medications, electrocardiography, echocardiography, vascular function assessment, carotid and abdominal ultrasound, bone density, coronary CTA and post-processing data. The primary outcome is the first occurrence of a cardiorenal composite endpoint. Participants will be followed for up to 5 years through active annual follow-up and passive monthly data updates to support risk stratification, real-world evidence generation, and CKM management pathway optimization.

Read the detailed description

This study is a single-center CKM patient registry with retrospective data entry and prospective lifecycle follow-up. A patient-centered master index will be established primarily on the basis of hospitalization identifiers to integrate multi-source hospital data, including discharge records, diagnoses, laboratory testing, medications, electrocardiography, echocardiography, baPWV/ABI, carotid ultrasound, abdominal ultrasound, bone density, coronary CTA and post-processing metrics, and clinical outcome events. A structured longitudinal database will be created to support standardized phenotyping, event adjudication, and repeat-assessment tracking. The primary objective is to build a dynamic registry platform for CKM-related inpatients and to support long-term follow-up, outcome surveillance, risk stratification, and real-world evidence generation. The study is planned for 5 years, from March 1, 2026 to February 28, 2031, with annual active follow-up and monthly passive data updates. Major outcomes include a time-to-first cardiorenal composite endpoint, all-cause mortality, 3-point major adverse cardiovascular events, heart failure hospitalization or cardiovascular death, and additional pre-specified cardiovascular, renal, metabolic, oncologic, cognitive, and imaging progression outcomes.

Conditions: Cardiovascular Diseases (CVD), Chronic Kidney Disease, Metabolic Diseases, Cardiovascular-kidney-metabolic Syndrome
Keywords: CKM syndrome, Cardiovascular-Kidney-Metabolic, Patient registry, Real-world data
Medical subject headings: Cardiovascular Diseases, Renal Insufficiency, Chronic, Metabolic Diseases

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Study groups in NCT07547098
Study group	Role	What they receive
CKM Registry Cohort		Adults aged 18 to 80 years receiving inpatient care at the First Affiliated Hospital of Fujian Medical University with cardiovascular disease, kidney disease, metabolic disease, or key examination and laboratory data supporting CKM phenotyping, enrolled for structured data collection and longitudinal follow-up.

What is being measured

The primary outcome is the main question the study is designed to answer.

First occurrence of a cardiorenal composite endpoint
Time to first occurrence of cardiovascular death or kidney disease progression, defined as sustained decline in eGFR of at least 40% from baseline, sustained eGFR below 15 mL/min/1.73 m², initiation of maintenance dialysis, kidney transplantation, or renal death.
Measured: Up to 5 years from enrollment

Secondary outcomes (10)

All-cause mortality
Time to death from any cause during follow-up.
Measured: Up to 5 years from enrollment
3-point major adverse cardiovascular events (3-point MACE)
Time to first occurrence of cardiovascular death, nonfatal myocardial infarction, or nonfatal ischemic stroke.
Measured: Up to 5 years from enrollment
First hospitalization for heart failure or cardiovascular death
Time to first hospitalization for heart failure or cardiovascular death during follow-up.
Measured: Up to 5 years from enrollment.
Nonfatal Myocardial Infarction
First occurrence of nonfatal myocardial infarction during follow-up.
Measured: Up to 5 years from enrollment
Nonfatal Ischemic Stroke
First occurrence of nonfatal ischemic stroke during follow-up.
Measured: Up to 5 years from enrollment
Incident Atrial Fibrillation
New-onset atrial fibrillation among participants without a history of atrial fibrillation at baseline, confirmed by 12-lead electrocardiography, Holter monitoring, or inpatient/outpatient clinical diagnosis during follow-up.
Measured: Up to 5 years from enrollment
Coronary Revascularization
First occurrence of coronary revascularization, including percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG), during follow-up.
Measured: Up to 5 years from enrollment
Aortic Disease Intervention
First occurrence of endovascular or surgical intervention for aortic dissection, aortic aneurysm, penetrating aortic ulcer, or other aortic diseases during follow-up.
Measured: Up to 5 years from enrollment
Peripheral Vascular Events
First occurrence of peripheral vascular events, including acute limb ischemia, peripheral arterial revascularization, or major amputation due to vascular causes.
Measured: From enrollment until the date of first documented peripheral vascular event, death, loss to follow-up, or end of study, whichever came first, assessed up to 5 years.
Incident Diabetes Mellitus
New-onset diabetes mellitus among participants without diabetes at baseline, defined as a new clinical diagnosis of diabetes, initiation of glucose-lowering therapy, or laboratory evidence meeting diagnostic criteria during follow-up.
Measured: Up to 5 years from enrollment

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

1 Mar 202628 Feb 2031

First posted23 Apr 2026
Study start1 Mar 2026
Primary completion28 Feb 2031 (estimated)
Study completion28 Feb 2031 (estimated)

Resources

Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
Publications (16)Papers the sponsor has linked to this study.
Other trials for Cardiovascular Diseases (CVD)Studies of the same condition, open and under way.
More trials run by First Affiliated Hospital of Fujian Medical UniversityThe sponsor's other registered studies.
What the trial phases meanHow a treatment moves from first tests in people to approval.

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design

Study type: Observational
Observational model: Cohort
Time perspective: Other
Enrolment: 8,000 participants (estimated)
Target duration: 5 Years

IDs, dates and publications

ClinicalTrials.gov ID: NCT07547098
Sponsor's protocol ID: MRCTA,ECFAH of FMU[2026]046
Acronym: CKM-LCBP
Status last verified: Mar 2026
First submitted: 13 Apr 2026
Last updated: 23 Apr 2026
Results posted: No
Data monitoring committee: Yes
FDA-regulated drug: No
FDA-regulated device: No
Individual data sharing: Undecided: De-identified individual participant data may be considered for sharing subject to institutional approval, data security requirements, ethics approval where applicable, and the minimum necessary principle. A formal data-sharing policy has not yet been finalized at the time of registration.

Publications

Duan L, Yang H, Chen Z, Zhao J, Yang J, Cai D. Dietary antioxidants and mortality in early-stage CKM syndrome: insights from NHANES. Nutr Metab (Lond). 2025 Jul 16;22(1):77. doi: 10.1186/s12986-025-00974-5.
PubMed 40671108
Chen Q, Zhu Y, Gao J, Ni W, Liu S, Rui F, Bai X, Geng N, Jin R, Sun Y, Chen Y, Fan Z, Wu C, Qi X, Shi J, Li J. Cardiovascular-kidney-metabolic (CKM) syndrome is associated with increased mortality in individuals with metabolic dysfunction-associated steatotic liver disease (MASLD). Commun Med (Lond). 2025 Nov 21;5(1):492. doi: 10.1038/s43856-025-01195-w.
PubMed 41272273
Li N, Li Y, Cui L, Shu R, Song H, Wang J, Chen S, Liu B, Shi H, Gao H, Huang T, Gao X, Geng T, Wu S. Association between different stages of cardiovascular-kidney-metabolic syndrome and the risk of all-cause mortality. Atherosclerosis. 2024 Oct;397:118585. doi: 10.1016/j.atherosclerosis.2024.118585. Epub 2024 Aug 30.
PubMed 39255681
Rumrill SM, Shlipak MG. The New Cardiovascular-Kidney-Metabolic (CKM) Syndrome: An Opportunity for CKD Detection and Treatment in Primary Care. Am J Kidney Dis. 2025 Apr;85(4):399-402. doi: 10.1053/j.ajkd.2024.09.016. Epub 2024 Dec 18. No abstract available.
PubMed 39706244
Chen Y, Wu S, Liu H, Zhong Z, Bucci T, Wang Y, Zhao M, Liu Y, Yang Z, Gue Y, McDowell G, Huang B, Lip GYH. Role of oxidative balance score in staging and mortality risk of cardiovascular-kidney-metabolic syndrome: Insights from traditional and machine learning approaches. Redox Biol. 2025 Apr;81:103588. doi: 10.1016/j.redox.2025.103588. Epub 2025 Mar 7.
PubMed 40073760
Zheng Q, Cao Z, Teng J, Lu Q, Huang P, Zhou J. Association between atherogenic index of plasma with all-cause and cardiovascular mortality in individuals with Cardiovascular-Kidney-Metabolic syndrome. Cardiovasc Diabetol. 2025 Apr 26;24(1):183. doi: 10.1186/s12933-025-02742-4.
PubMed 40287685
Xie Z, Yu C, Cui Q, Zhao X, Zhuang J, Chen S, Guan H, Li J. Global Burden of the Key Components of Cardiovascular-Kidney-Metabolic Syndrome. J Am Soc Nephrol. 2025 Mar 5;36(8):1572-1584. doi: 10.1681/ASN.0000000658.
PubMed 40042920
Guerrero-Mauvecin J, Villar-Gomez N, Mino-Izquierdo L, Povo-Retana A, Ramos AM, Ruiz-Hurtado G, Sanchez-Nino MD, Ortiz A, Sanz AB. Antioxidant Effects of SGLT2 Inhibitors on Cardiovascular-Kidney-Metabolic (CKM) Syndrome. Antioxidants (Basel). 2025 Jun 9;14(6):701. doi: 10.3390/antiox14060701.
PubMed 40563333
Zhu R, Wang R, He J, Wang L, Chen H, Niu X, Sun Y, Guan Y, Gong Y, Zhang L, An P, Li K, Ren F, Xu W, Guo J. Prevalence of Cardiovascular-Kidney-Metabolic Syndrome Stages by Social Determinants of Health. JAMA Netw Open. 2024 Nov 4;7(11):e2445309. doi: 10.1001/jamanetworkopen.2024.45309.
PubMed 39556396
Papadakis Z. Exercise in CKM syndrome progression: a stage-specific approach to cardiovascular, metabolic, and renal health. Cardiovasc Diabetol. 2025 Dec 20;24(1):462. doi: 10.1186/s12933-025-03029-4.
PubMed 41421989
Kittelson KS, Junior AG, Fillmore N, da Silva Gomes R. Cardiovascular-kidney-metabolic syndrome - An integrative review. Prog Cardiovasc Dis. 2024 Nov-Dec;87:26-36. doi: 10.1016/j.pcad.2024.10.012. Epub 2024 Oct 30.
PubMed 39486671
Gao C, Gao S, Zhao R, Shen P, Zhu X, Yang Y, Duan C, Wang Y, Ni H, Zhou L, Xiang Y, Li M, Xu Z, Wang Y, Yang H, Zhao C. Association between systemic immune-inflammation index and cardiovascular-kidney-metabolic syndrome. Sci Rep. 2024 Aug 19;14(1):19151. doi: 10.1038/s41598-024-69819-0.
PubMed 39160192
Ferdinand KC. An overview of cardiovascular-kidney-metabolic syndrome. Am J Manag Care. 2024 Dec;30(10 Suppl):S181-S188. doi: 10.37765/ajmc.2024.89670.
PubMed 39705194
Javaid A, Hariri E, Ozkan B, Lang K, Khan SS, Rangaswami J, Stone NJ, Blumenthal RS, Ndumele CE. Cardiovascular-Kidney-Metabolic (CKM) Syndrome: A Case-Based Narrative Review. Am J Med Open. 2025 Jan 30;13:100089. doi: 10.1016/j.ajmo.2025.100089. eCollection 2025 Jun.
PubMed 40104608
Claudel SE, Schmidt IM, Waikar SS, Verma A. Cumulative Incidence of Mortality Associated with Cardiovascular-Kidney-Metabolic (CKM) Syndrome. J Am Soc Nephrol. 2025 Feb 11;36(7):1343-1351. doi: 10.1681/ASN.0000000637.
PubMed 39932805

Interested in taking part?

Dajun Chai

008659187981637

dajunchai-fy@fjmu.edu.cn

Talk to your doctor first and take this page with you. Only the study team can confirm whether you can join.

Questions to ask the study team

What is the study trying to find out?
What would I need to do, and how often would I visit?
Could I receive a placebo instead of the treatment?
What are the possible risks and benefits for me?
Will it cost me anything? Are travel or time paid for?
Can I keep seeing my own doctor during the study?
What happens when the study ends?

See sites and contacts

Active, not recruitingPhase 3
ENDOTHELION Study Group: Effect of Bosentan in NAION Patients
Ischemic Optic Neuropathy
Active, not recruiting
Digital Reinforcement of Motivational Interviewing Micro-Skills Among Primary Care Healthcare Professionals
Hypertension (Without Type 2 Diabetes Mellitus)
Not yet recruitingPhase 2
Study of YKST02 in Adults With Relapsed or Refractory Multiple Myeloma
Relapsed or Refractory Multiple Myeloma (RRMM)
RecruitingPhase 2
Engaging T-cells to Eliminate MRD in Newly Diagnosed Myeloma Optimizing Response With Talquetmab and Teclistamab (ROTATE)
Multiple Myeloma
Recruiting
PAW-Hydrogel for Chronic Wound Healing
Diabetic Foot Ulcer (DFU), Pressure Ulcer (PU)

All Cardiovascular Diseases (CVD) trials

Study at a glance

From the registry record, last updated by the sponsor on 23 Apr 2026. Recruitment status is as the sponsor reported it: confirm with the study team.

Official title: Study on Construction of Whole Lifecycle Cohort, Big Data Management and Clinical Prognosis of Cardio-Renal-Metabolic (CKM) Syndrome
ClinicalTrials.gov ID: NCT07547098
Acronym / sponsor ID: CKM-LCBP / MRCTA,ECFAH of FMU[2026]046
Conditions: Cardiovascular Diseases (CVD), Chronic Kidney Disease, Metabolic Diseases, Cardiovascular-kidney-metabolic Syndrome
Keywords: CKM syndrome, Cardiovascular-Kidney-Metabolic, Patient registry, Real-world data
Study type: Observational
Recruitment status: Recruiting
Enrolment: 8,000 participants (estimated)
Lead sponsor: First Affiliated Hospital of Fujian Medical UniversityUniversity, hospital or other
Study start: 1 Mar 2026 (actual)
Primary completion: 28 Feb 2031 (estimated)
Study completion: 28 Feb 2031 (estimated)
First posted: 23 Apr 2026 (actual)
Results: Not posted in the source record

Clinical summary

The research question as the sponsor registered it. This describes what the study plans to test, not what it found.

Detailed description

Study design

Observational model: Cohort
Time perspective: Other
Target follow-up: 5 Years
Number of arms: 1

Arm	Type	Receives
CKM Registry Cohort	–	–Adults aged 18 to 80 years receiving inpatient care at the First Affiliated Hospital of Fujian Medical University with cardiovascular disease, kidney disease, metabolic disease, or key examination and laboratory data supporting CKM phenotyping, enrolled for structured data collection and longitudinal follow-up.

Who may qualify

Ages: 18 to 80 years
Sex: All
Healthy volunteers: Not accepted
Age groups: Adult, Older adult
Study population: Hospital-based adult CKM-related inpatients at the First Affiliated Hospital of Fujian Medical University with available clinical and multimodal examination data for longitudinal registry follow-up.

Key inclusion criteria (6 listed)

Age 18 years or older.
Inpatient record available at the First Affiliated Hospital of Fujian Medical University with retrievable identifiers for data linkage.
Cardiovascular disease, kidney disease, metabolic disease, or key examination/laboratory information supporting CKM phenotyping.
Willingness to participate and provision of written informed consent.
Ability to complete baseline assessment and follow-up.

Key exclusion criteria (6 listed)

Refusal to provide written informed consent.
Severe psychiatric disease or cognitive impairment precluding participation.
End-stage disease with expected survival less than 1 year.
Long-term absence more than 6 months preventing reliable follow-up.
Participation in another clinical study that may interfere with endpoint adjudication.

Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.

Primary outcome

First occurrence of a cardiorenal composite endpoint
Time frame: Up to 5 years from enrollment
Time to first occurrence of cardiovascular death or kidney disease progression, defined as sustained decline in eGFR of at least 40% from baseline, sustained eGFR below 15 mL/min/1.73 m², initiation of maintenance dialysis, kidney transplantation, or renal death.

10 secondary outcomes

All-cause mortality
Time frame: Up to 5 years from enrollment
3-point major adverse cardiovascular events (3-point MACE)
Time frame: Up to 5 years from enrollment
First hospitalization for heart failure or cardiovascular death
Time frame: Up to 5 years from enrollment.
Nonfatal Myocardial Infarction
Time frame: Up to 5 years from enrollment
Nonfatal Ischemic Stroke
Time frame: Up to 5 years from enrollment
Incident Atrial Fibrillation
Time frame: Up to 5 years from enrollment
Coronary Revascularization
Time frame: Up to 5 years from enrollment
Aortic Disease Intervention
Time frame: Up to 5 years from enrollment
Peripheral Vascular Events
Time frame: From enrollment until the date of first documented peripheral vascular event, death, loss to follow-up, or end of study, whichever came first, assessed up to 5 years.
Incident Diabetes Mellitus
Time frame: Up to 5 years from enrollment

Results and safety

This study is still under way. Results are not available in the source record yet.

Research links

Official record on ClinicalTrials.govLast updated by the sponsor 23 Apr 2026.
Background: PubMed 40671108Duan L, Yang H, Chen Z, Zhao J, Yang J, Cai D. Dietary antioxidants and mortality in early-stage CKM syndrome: insights from NHANES. Nutr Metab (Lond). 2025 Jul 16;22(1):77. doi: 10.1186/s12986-025-00974-5.
Background: PubMed 41272273Chen Q, Zhu Y, Gao J, Ni W, Liu S, Rui F, Bai X, Geng N, Jin R, Sun Y, Chen Y, Fan Z, Wu C, Qi X, Shi J, Li J. Cardiovascular-kidney-metabolic (CKM) syndrome is associated with increased mortality in individuals with metabolic dysfunction-associated steatotic liver disease (MASLD). Commun Med (Lond). 2025 Nov 21;5(1):492. doi: 10.1038/s43856-025-01195-w.
Background: PubMed 39255681Li N, Li Y, Cui L, Shu R, Song H, Wang J, Chen S, Liu B, Shi H, Gao H, Huang T, Gao X, Geng T, Wu S. Association between different stages of cardiovascular-kidney-metabolic syndrome and the risk of all-cause mortality. Atherosclerosis. 2024 Oct;397:118585. doi: 10.1016/j.atherosclerosis.2024.118585. Epub 2024 Aug 30.
Background: PubMed 39706244Rumrill SM, Shlipak MG. The New Cardiovascular-Kidney-Metabolic (CKM) Syndrome: An Opportunity for CKD Detection and Treatment in Primary Care. Am J Kidney Dis. 2025 Apr;85(4):399-402. doi: 10.1053/j.ajkd.2024.09.016. Epub 2024 Dec 18. No abstract available.
Background: PubMed 40073760Chen Y, Wu S, Liu H, Zhong Z, Bucci T, Wang Y, Zhao M, Liu Y, Yang Z, Gue Y, McDowell G, Huang B, Lip GYH. Role of oxidative balance score in staging and mortality risk of cardiovascular-kidney-metabolic syndrome: Insights from traditional and machine learning approaches. Redox Biol. 2025 Apr;81:103588. doi: 10.1016/j.redox.2025.103588. Epub 2025 Mar 7.
Background: PubMed 40287685Zheng Q, Cao Z, Teng J, Lu Q, Huang P, Zhou J. Association between atherogenic index of plasma with all-cause and cardiovascular mortality in individuals with Cardiovascular-Kidney-Metabolic syndrome. Cardiovasc Diabetol. 2025 Apr 26;24(1):183. doi: 10.1186/s12933-025-02742-4.
Background: PubMed 40042920Xie Z, Yu C, Cui Q, Zhao X, Zhuang J, Chen S, Guan H, Li J. Global Burden of the Key Components of Cardiovascular-Kidney-Metabolic Syndrome. J Am Soc Nephrol. 2025 Mar 5;36(8):1572-1584. doi: 10.1681/ASN.0000000658.
Background: PubMed 40563333Guerrero-Mauvecin J, Villar-Gomez N, Mino-Izquierdo L, Povo-Retana A, Ramos AM, Ruiz-Hurtado G, Sanchez-Nino MD, Ortiz A, Sanz AB. Antioxidant Effects of SGLT2 Inhibitors on Cardiovascular-Kidney-Metabolic (CKM) Syndrome. Antioxidants (Basel). 2025 Jun 9;14(6):701. doi: 10.3390/antiox14060701.
Background: PubMed 39556396Zhu R, Wang R, He J, Wang L, Chen H, Niu X, Sun Y, Guan Y, Gong Y, Zhang L, An P, Li K, Ren F, Xu W, Guo J. Prevalence of Cardiovascular-Kidney-Metabolic Syndrome Stages by Social Determinants of Health. JAMA Netw Open. 2024 Nov 4;7(11):e2445309. doi: 10.1001/jamanetworkopen.2024.45309.
Background: PubMed 41421989Papadakis Z. Exercise in CKM syndrome progression: a stage-specific approach to cardiovascular, metabolic, and renal health. Cardiovasc Diabetol. 2025 Dec 20;24(1):462. doi: 10.1186/s12933-025-03029-4.
Background: PubMed 39486671Kittelson KS, Junior AG, Fillmore N, da Silva Gomes R. Cardiovascular-kidney-metabolic syndrome - An integrative review. Prog Cardiovasc Dis. 2024 Nov-Dec;87:26-36. doi: 10.1016/j.pcad.2024.10.012. Epub 2024 Oct 30.
Background: PubMed 39160192Gao C, Gao S, Zhao R, Shen P, Zhu X, Yang Y, Duan C, Wang Y, Ni H, Zhou L, Xiang Y, Li M, Xu Z, Wang Y, Yang H, Zhao C. Association between systemic immune-inflammation index and cardiovascular-kidney-metabolic syndrome. Sci Rep. 2024 Aug 19;14(1):19151. doi: 10.1038/s41598-024-69819-0.
Individual participant dataSharing planned: Undecided. De-identified individual participant data may be considered for sharing subject to institutional approval, data security requirements, ethics approval where applicable, and the minimum necessary principle. A formal data-sharing policy has not yet been finalized at the time of registration.

Related trials for Cardiovascular Diseases (CVD)

Active, not recruitingPhase 3
ENDOTHELION Study Group: Effect of Bosentan in NAION Patients
Ischemic Optic Neuropathy
Active, not recruiting
Digital Reinforcement of Motivational Interviewing Micro-Skills Among Primary Care Healthcare Professionals
Hypertension (Without Type 2 Diabetes Mellitus)
Not yet recruitingPhase 2
Study of YKST02 in Adults With Relapsed or Refractory Multiple Myeloma
Relapsed or Refractory Multiple Myeloma (RRMM)
RecruitingPhase 2
Engaging T-cells to Eliminate MRD in Newly Diagnosed Myeloma Optimizing Response With Talquetmab and Teclistamab (ROTATE)
Multiple Myeloma
Recruiting
PAW-Hydrogel for Chronic Wound Healing
Diabetic Foot Ulcer (DFU), Pressure Ulcer (PU)

Referral and contact

AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.

Dajun Chai contact

008659187981637

dajunchai-fy@fjmu.edu.cn

Hailin Zhang contact

824224843@qq.com

Dajun Chai principal investigator

First Affiliated Hospital of Fujian Medical University

1 site in 1 country: see every site and its status.

Questions about this trial

What is this clinical trial studying?

An observational study of Cardiovascular Diseases (CVD) and Chronic Kidney Disease, run by First Affiliated Hospital of Fujian Medical University at 1 site in China.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 6 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 23 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Dajun Chai (008659187981637, dajunchai-fy@fjmu.edu.cn), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

First occurrence of a cardiorenal composite endpoint (time frame: Up to 5 years from enrollment). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT07547098, which also lists 16 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 23 Apr 2026.